Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 9, 2019 | Erdafitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BALVERSA (DIN 02493217) under ATC L01EN01 ERDAFITINIB. Indications are not published in the Drug Product Database —… | DIN02493217 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 27, 2019 | Axicabtagene Ciloleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as YESCARTA (DIN 02485648) under ATC L01XL03 AXICABTAGENE CILOLEUCEL. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2019 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRAZIMERA (DIN 02483475) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02483475 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 25, 2019 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZIRABEV (DIN 02489449) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02489449 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 1, 2019 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as MVASI (DIN 02470756) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see… | DIN02470756 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 3, 2019 | Abemaciclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VERZENIO (DIN 02487136) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database —… | DIN02487136 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 26, 2019 | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ GEFITINIB (DIN 02487748) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product… | DIN02487748 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 24, 2019 | Cemiplimab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LIBTAYO (DIN 02487144) under ATC L01FF06 CEMIPLIMAB. Indications are not published in the Drug Product Database — see… | DIN02487144 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 23, 2019 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02474891) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 29, 2019 | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-BUSULFAN (DIN 02477343) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product Database —… | DIN02477343 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 27, 2019 | Enasidenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDHIFA (DIN 02485435) under ATC L01XM01 ENASIDENIB. Indications are not published in the Drug Product Database — see… | DIN02485435 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 15, 2019 | Pralatrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as FOLOTYN (DIN 02481820) under ATC L01BA05 PRALATREXATE%. Indications are not published in the Drug Product Database —… | DIN02481820 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 20, 2018 | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02468921) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product… | DIN02468921 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 24, 2018 | Trastuzumab Emtansine | Health Canada CA | cancer not stated in this record | Marketed in Canada as KADCYLA (DIN 02473224) under ATC L01FD03 TRASTUZUMAB EMTANSINE. Indications are not published in the Drug Product… | DIN |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 13, 2019 | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-GEFITINIB (DIN 02491796) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database… | DIN02491796 | withdrawnsource: Dormantsince Mar 1, 2026 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 22, 2019 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRAZIMERA (DIN 02483467) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02483467 | approvedsource: Marketed | health-canada-dpd |
| Oct 21, 2019 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02484129) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02484129 | approvedsource: Marketed | health-canada-dpd |
| Oct 21, 2019 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02484056) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02484056 | approvedsource: Marketed | health-canada-dpd |
| Oct 16, 2019 | Atezolizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECENTRIQ (DIN 02492393) under ATC L01FF05 ATEZOLIZUMAB. Indications are not published in the Drug Product Database —… | DIN02492393 | approvedsource: Marketed | health-canada-dpd |
| Oct 8, 2019 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZEULIDE DEPOT (DIN 02462699) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product… | DIN02462699 | approvedsource: Marketed | health-canada-dpd |
| Oct 8, 2019 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZEULIDE DEPOT (DIN 02429977) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product… | DIN02429977 | approvedsource: Marketed | health-canada-dpd |
| Oct 2, 2019 | Acalabrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CALQUENCE (DIN 02491788) under ATC L01EL02 ACALABRUTINIB. Indications are not published in the Drug Product Database… | DIN02491788 | withdrawnsource: Dormantsince Jul 25, 2025 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 25, 2019 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZIRABEV (DIN 02489430) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02489430 | approvedsource: Marketed | health-canada-dpd |
| Sep 4, 2019 | Larotrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VITRAKVI (DIN 02490331) under ATC L01EX12 LAROTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02490331 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 1, 2019 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as MVASI (DIN 02470748) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see… | DIN02470748 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 3, 2019 | Abemaciclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VERZENIO (DIN 02487128) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database —… | DIN02487128 | approvedsource: Marketed | health-canada-dpd |
| Jul 3, 2019 | Abemaciclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VERZENIO (DIN 02487101) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database —… | DIN02487101 | approvedsource: Marketed | health-canada-dpd |
| Jul 3, 2019 | Abemaciclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VERZENIO (DIN 02487098) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database —… | DIN02487098 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 31, 2026 |
| health-canada-dpd |
| Jun 25, 2019 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOLAK (DIN 02485346) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database — see… | DIN02485346 | approvedsource: Marketed | health-canada-dpd |
| Jun 6, 2019 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OGIVRI (DIN 02474433) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database — see… | DIN02474433 | approvedsource: Marketed | health-canada-dpd |
| Jun 6, 2019 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OGIVRI (DIN 02474425) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database — see… | DIN02474425 | approvedsource: Marketed | health-canada-dpd |
| Jun 6, 2019 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 02473771) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02473771 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 24, 2019 | Cemiplimab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LIBTAYO (DIN 02487152) under ATC L01FF06 CEMIPLIMAB. Indications are not published in the Drug Product Database — see… | DIN02487152 | withdrawnsource: Cancelled Post Marketsince Dec 8, 2023 | health-canada-dpd |
| May 24, 2019 | Tisagenlecleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as KYMRIAH (DIN 02480514) under ATC L01XL04 TISAGENLECLEUCEL. Indications are not published in the Drug Product Database… | DIN02480514 | approvedsource: Marketed | health-canada-dpd |
| May 17, 2019 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TASIGNA (DIN 02481715) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see… | DIN02481715 | withdrawnsource: Cancelled Post Marketsince Oct 4, 2023 | health-canada-dpd |
| May 8, 2019 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ERLOTINIB (DIN 02483939) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02483939 | withdrawnsource: Dormantsince Dec 1, 2021 | health-canada-dpd |
| May 8, 2019 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ERLOTINIB (DIN 02483920) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02483920 | withdrawnsource: Dormantsince Oct 1, 2021 | health-canada-dpd |
| May 8, 2019 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ERLOTINIB (DIN 02483912) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02483912 | withdrawnsource: Dormantsince May 1, 2021 | health-canada-dpd |
| May 1, 2019 | Dinutuximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as UNITUXIN (DIN 02483076) under ATC L01FX06 DINUTUXIMAB BETA. Indications are not published in the Drug Product… | DIN02483076 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 23, 2019 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02474735) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02474735 | approvedsource: Marketed | health-canada-dpd |
| Apr 22, 2019 | Lorlatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LORBRENA (DIN 02485974) under ATC L01ED05 LORLATINIB. Indications are not published in the Drug Product Database —… | DIN02485974 | approvedsource: Marketed | health-canada-dpd |
| Apr 22, 2019 | Lorlatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LORBRENA (DIN 02485966) under ATC L01ED05 LORLATINIB. Indications are not published in the Drug Product Database —… | DIN02485966 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 25, 2019 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB (DIN 02456176) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product Database —… | DIN02456176 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 30, 2023 |
| health-canada-dpd |
| Feb 27, 2019 | Enasidenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDHIFA (DIN 02485427) under ATC L01XM01 ENASIDENIB. Indications are not published in the Drug Product Database — see… | DIN02485427 | withdrawnsource: Cancelled Post Marketsince Jun 30, 2023 | health-canada-dpd |
| Feb 27, 2019 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as LAPELGA (DIN 02474565) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02474565 | approvedsource: Marketed | health-canada-dpd |
| Feb 1, 2019 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTION (DIN 02483610) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02483610 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 15, 2019 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-FULVESTRANT INJECTION (DIN 02460130) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug… | DIN02460130 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Apr 13, 2023 |
| health-canada-dpd |
| Nov 6, 2018 | Yttrium-90 | Health Canada CA | cancer not stated in this record | Marketed in Canada as YTTRIGA (DIN 02470543) under ATC V10AA YTTRIUM 90 Y COMPOUNDS. Indications are not published in the Drug Product… | DIN02470543 | withdrawnsource: Dormantsince Sep 17, 2020 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 18, 2018 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-PEMETREXED (DIN 02429195) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product… | DIN02429195 | approvedsource: Marketed | health-canada-dpd |
| Oct 12, 2018 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as HERCEPTIN SC (DIN 02480697) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database… | DIN02480697 | approvedsource: Marketed | health-canada-dpd |